Pathology News
admin

About admin@pathologynews.com

This author has not yet filled in any details.
So far admin@pathologynews.com has created 1089 blog entries.

November 2022

Artificial intelligence methods may replace histochemical staining

2022-11-02T13:23:30+00:00

The diagram of the training and testing schemes for the defocused image virtual staining framework. (a) Training of the standard in-focus image virtual staining network. Aligned pairs of in-focus autofluorescence images captured before the histochemical staining process and the brightfield images of the same tissue sections after the histochemical staining are used. (b) Training of the autofocusing network (Deep-R). Autofluorescence images (defocused) were randomly picked from z-stacks (ranging from -2 μm to 2 μm) as the network inputs. The network target is the corresponding in-focus autofluorescence image. (c) Testing of the defocused image virtual staining framework. Credit: Intelligent Computing (2022). DOI: 10.34133/2022/9818965 Pathologists observe tissue samples by staining them first. However, the standard procedures for staining tissue samples in histopathology are time-consuming and require specialized laboratory infrastructure, chemical reagents, and skilled technicians. Uncertainty in tissue staining in the handling of different laboratories and histology technicians may lead to misdiagnosis. In addition, the original tissue sample is not preserved by these histochemical staining techniques currently in use since each step of the procedures has irreversible impact on the sample. With the advancement of artificial intelligence (AI), researchers are using AI techniques to improve pathology workflow. A recent study from the University of California Los Angeles (UCLA) used deep neural networks to virtually stain microscopic images of unlabeled tissue. The research was published in Intelligent Computing. Deep neural networks have already been applied to stain unlabeled tissue section images, avoiding different laborious and time-consuming histochemical staining processes. There are, however, some bottlenecks. "In all the label-free virtual staining methods, the acquisition of in-focus images of the unlabeled tissue sections is essential. In general, focusing is a critical but time-consuming step in scanning optical microscopy," the authors said. The most widely used autofocusing method demands many focus points across the tissue slide area with high focusing precision, and the best focal plane is determined by an iterative search algorithm, which is time consuming and may introduce photodamage and photobleaching on the samples. To overcome these problems, the authors present a new deep learning-based fast virtual staining framework. They say that "this framework uses an autofocusing neural network (termed Deep-R) to digitally refocus the defocused autofluorescence images. Then a virtual staining network is used to transform the refocused images into virtually stained images." Compared to the standard virtual staining framework, the new framework demonstrated by the authors uses fewer focal points and reduces the focusing precision for each focus point to acquire coarsely-focused whole slide autofluorescence images of tissue. This new virtual staining framework can significantly reduce the time for autofocusing and the entire image acquisition process. The authors say that "the deep learning-based framework decreases the total image acquisition time needed for virtual staining of a label-free whole slide images (WSI) by ~32%, also resulting in a ~89% decrease in the autofocusing time per tissue slide." Despite loss of image sharpness and contrast compared to standard virtual staining frameworks, high quality staining can still be produced, closely matching the corresponding histochemically stained ground truth images. Furthermore, this framework can also be used as an add-on module to improve the robustness of the standard virtual staining framework. This fast virtual staining framework will have more development prospects in the future. "This fast virtual staining workflow can also be expanded to many other stains, such as Masson's Trichrome stain, Jones' silver stain, and immunohistochemical (IHC) stains," the authors said. "Although the virtual staining approach presented here was demonstrated based on the autofluorescence imaging of unlabeled tissue sections, it can also be used to speed up the virtual staining workflow of other label-free microscopy modalities." More information: Yijie Zhang et al, Virtual Staining of Defocused Autofluorescence Images of Unlabeled Tissue Using Deep Neural Networks, Intelligent Computing (2022). DOI: 10.34133/2022/9818965 Provided by Intelligent Computing

Artificial intelligence methods may replace histochemical staining2022-11-02T13:23:30+00:00

Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma

2022-11-01T14:39:20+00:00

Proscia today unveiled study results on a new artificial intelligence (AI) that predicts diagnostic agreement for melanoma. The findings highlight the potential of the technology to improve diagnostic accuracy for melanoma and other diseases with low pathologist concordance.

Proscia Presents Study Results On New Artificial Intelligence That Predicts Diagnostic Concordance For Melanoma2022-11-01T14:39:20+00:00

October 2022

Deep Bio Inc. successfully integrates DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs

2022-10-31T09:46:09+00:00

DeepDx® Prostate is a clinically validated and CEmarked AI-based image analysis algorithm for prostate core needle biopsy analysis that detects cancer and grades its severity according to the Gleason scoring system. DeepDx® Prostate is designed to alleviate the shortage of pathologists and their heavy workload, while reducing diagnostic subjectivity and variability. The DeepDx® Prostate algorithm analyses whole slide images of H&E stained biopsy specimens and provides color visualization and gland-level segmentation based on Gleason patterns. In addition, it supplies the proportion of each Gleason pattern among the three patterns, and automatically provides measurements of the total tissue and tumor lengths. The latest validation study of the DeepDx® algorithm demonstrated at 99% sensitivity and 97% specificity. Moreover, the algorithm has successfully analyzed more than 700,000 tissues cores between 2019 and 2021.

Deep Bio Inc. successfully integrates DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs2022-10-31T09:46:09+00:00

Deep Bio Acquires ISO 27001 Certification for Information Security Management

2022-10-30T10:38:28+00:00

Deep Bio: Enhanced security and reliability through adherence to the globally recognized information security standardsSEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has acquired ISO/IEC 27001:2013 certification, the international information security management system standards.ISO/IEC 27001:2013 specifies the requirements for establishing, implementing, maintaining, and improving an information security management system and provides a risk management process so that organizations can accordingly keep their information safe. As the most widely-recognized certification for information security management, it strictly evaluates 144 criteria in 14 categories such as information security policy, security processes, security controls and services. By obtaining the certification, Deep Bio has demonstrated its commitment to protecting data through a systematic management for information security.“As we handle a myriad of medical data which require a more secure approach, we are very aware of the importance of information security above all else, and make every effort to build a thorough security management system,” said Sun Woo Kim, the CEO of Deep Bio. “Achieving the certification proves our robust data security management systems. We will keep renewing this certification so that our partners and customers can use our AI-based cancer diagnostic support software with confidence,” he mentioned.Deep Bio, which initiated AI-based pathology image analysis and cancer diagnosis research in Korea, is leading the digital transformation in pathology with Korea’s first approved AI-based cancer diagnostic support software DeepDx®-Prostate and AI-based prostate cancer severity-grading software DeepDx®-Prostate Pro. More importantly, the company plans to execute purchase agreements with five Korean hospitals for DeepDx®-Prostate Pro, through the Public Procurement Marketplace program run by the Korean Public Procurement Service (PPS).Deep Bio also continues to build its global presence through overseas partnerships with digital pathology platform providers in the US, Europe, and India, as well as conduct research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US. The company also has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, among others.About Deep BioDeep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. Our vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. To learn more, visit http://www.deepbio.co.kr.DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores and grade groups. Extensively tested at 4 US CLIA labs (700k+ cores from 2019 to 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability. To learn more, visit http://www.deepbio.co.krSOURCE: CISION PR Web

Deep Bio Acquires ISO 27001 Certification for Information Security Management2022-10-30T10:38:28+00:00

Pramana and Caris Life Sciences Collaborate to Digitize 1.5 Million Pathology Slides Annually

2022-10-29T15:05:48+00:00

Pramana, Inc., an AI-enabled health tech company modernizing the pathology sector, today announced a multi-year agreement with Caris Life Sciences (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. As part of the agreement, Pramana will digitize approximately 1.5 million slides per year with its family of intelligent scanning systems and advanced software, bringing efficiency to digital operations.

Pramana and Caris Life Sciences Collaborate to Digitize 1.5 Million Pathology Slides Annually2022-10-29T15:05:48+00:00

What Did PathVisions22 Reveal About the Future of Digital Pathology?

2022-10-28T15:04:23+00:00

Cranfield, UK, 25th October 2022 – After announcing a sold-out exhibition and attendee register, Pathology Visions 2022 was certainly not one to be missed. The halls of the MGM Grand buzzed with vendor and pathologist enthusiasm, speaking volumes to the significance of digital pathology following a notable rise in interest during the COVID-19 pandemic. After speaking to many vendors at the show and attending multiple conference sessions, we share our thoughts below on what the conference’s discourse revealed about digital pathology’s immediate future.

What Did PathVisions22 Reveal About the Future of Digital Pathology?2022-10-28T15:04:23+00:00

EIZO RadiForce MX243W – EIZO’s New Monitor for Microscope Images

2022-10-28T12:29:47+00:00

EIZO, the Japanese specialist in image reproduction solutions, announces the launch of a new 24.1" colour monitor. The RadiForce MX243W is a widescreen monitor and factory calibrated with a DICOM® -GSDF luminance characteristic.

EIZO RadiForce MX243W – EIZO’s New Monitor for Microscope Images2022-10-28T12:29:47+00:00

Deploying the Slide QC 2.0 network in HALO AI and HALO AP®

2025-06-04T11:41:08+00:00

In this 1-hour webinar, learn about the AI-powered Slide QC 2.0 network that was recently released in HALO AI 3.5 for automatically detecting and reporting artifacts in both research and clinical workflows. The Slide QC network can segment artifacts including tissue folds, air bubbles, out-of-focus regions, dust and pen marks. Learn how the network was developed and how it performs against external test sets. Furthermore, learn how to use it and how to add your own training regions to improve artifact detection in your individual workflows. By attending this webinar, you will also learn how you can deploy it in a clinical environment with HALO AP to improve lab efficiency. The Slide QC network can be used in a clinical environment both to flag slides with a high percentage of artifacts for review and to identify artifacts and exclude them from downstream image analysis.

Deploying the Slide QC 2.0 network in HALO AI and HALO AP®2025-06-04T11:41:08+00:00

HistoQC, an open-source way to control the quality of pathology images

2025-05-06T13:29:15+00:00

This episode’s guest, Andrew Janowczyk, is a computer scientist who has been active in the field of digital pathology since 2008. Before turning to the field of digital pathology he worked across the globe and across industries.

HistoQC, an open-source way to control the quality of pathology images2025-05-06T13:29:15+00:00
Go to Top